Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

Phase 2

Not yet recruiting

Conditions: Brentuximab Vedotin
Young Adult
PET Scan
Classical Hodgkin Lymphoma
Treatment
Child
Adolescent
Metabolic Response
Survival

Interventions: Drug: Brentuximab Vedotin for Injection
Radiation: response-adapted radiation
Drug: Doxorubicin
Drug: Etoposide
Drug: Prednisone
Drug: Cyclophosphamide
Drug: Dacarbazine
Drug: Tislelizumab Injection
Drug: Bedamustine

First Posted Date: 2024-08-20

Last Posted Date: 2024-08-20

Lead Sponsor: Children's Cancer Group, China

Target Recruit Count: 96

Registration Number: NCT06563245

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Phase 2

Recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: Tislelizumab
Drug: Etoposide
Drug: Carboplatin or Cisplatin
Radiation: Thoracic radiotherapy

First Posted Date: 2024-08-05

Last Posted Date: 2024-08-05

Lead Sponsor: Second Hospital of Shanxi Medical University

Target Recruit Count: 40

Registration Number: NCT06536868

Locations: 🇨🇳
Jinzhong third people's hospital, Jinzhong, Shanxi, China
🇨🇳
Jincheng General Hospital, Jincheng, Shanxi, China
🇨🇳
Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China

and more 3 locations

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Phase 2

Recruiting

Conditions: Neuroblastoma
Childhood Neuroblastoma
High-risk Neuroblastoma

Interventions: Biological: DANYELZA
Biological: Sargramostim
Drug: Cytoxan
Drug: Topotecan
Drug: Vincristine
Drug: Doxorubicin
Drug: Ifosfamide
Drug: Etoposide
Drug: Carboplatin
Drug: Irinotecan
Drug: Temozolomide

First Posted Date: 2024-07-30

Last Posted Date: 2024-11-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT06528496

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase 2

Recruiting

Conditions: High Grade Glioma
CNS Tumor

Interventions: Drug: Entrectinib
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Carboplatin
Biological: G-CSF
Biological: Pegfilgrastim
Procedure: Surgery

First Posted Date: 2024-07-30

Last Posted Date: 2024-12-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 52

Registration Number: NCT06528691

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

Phase 3

Recruiting

Conditions: Non-Hodgkin's Lymphoma
Hematopoietic Stem Cell Mobilization

Interventions: Drug: Etoposide
Combination Product: CHOP
Drug: Cytarabine
Combination Product: Hyper-CVAD
Drug: PEG-rhG-CSF
Combination Product: ID-MTX + Ara-C
Drug: G-CSF
Combination Product: DA-EPOCH
Combination Product: GDP
Combination Product: GDPE
Combination Product: ICE
Combination Product: DICE

First Posted Date: 2024-07-25

Last Posted Date: 2024-07-25

Lead Sponsor: The Affiliated People's Hospital of Ningbo University

Target Recruit Count: 99

Registration Number: NCT06520163

Locations: 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
Lishui Central Hospital, Lishui, Zhejiang, China
🇨🇳
Dongyang People's Hospital, Dongyang, Zhejiang, China

and more 13 locations

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Phase 3

Recruiting

Conditions: Multiple Myeloma
Hematopoietic Stem Cell Mobilization

Interventions: Drug: Etoposide
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Pegfilgrastim
Drug: G-CSF

First Posted Date: 2024-07-25

Last Posted Date: 2024-07-25

Lead Sponsor: The Affiliated People's Hospital of Ningbo University

Target Recruit Count: 99

Registration Number: NCT06520176

Locations: 🇨🇳
Dongyang People's Hospital, Dongyang, Zhejiang, China
🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
The First Hospital of Jiaxing, Jiaxing, Zhejiang, China

and more 13 locations